Partial
Partially Aligned
Patient Risk:
Low
Summary
The claims about FDA approval date and that first approval covered COPD are not supported or contradicted by the provided FDA-approved prescribing information excerpt. The excerpt does support that TRELEGY ELLIPTA has COPD maintenance and asthma maintenance indications, but it does not contain approval-history details.
Category Scores
Accurate Statements
Unsupported Statements
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) received its initial U.S. FDA approval on September 18, 2017.
The provided prescribing information excerpt (Sections 1, 2, 3, 4, 5, 6, 7, 8, 12, 14) does not include FDA approval/approval-date history.
Trelegy Ellipta’s first FDA approval covered COPD (chronic obstructive pulmonary disease).
The provided prescribing information excerpt states current indications (COPD maintenance; asthma maintenance) but does not state what the first FDA approval covered or any approval-history sequencing.
Contradictions
Important Omissions
Label evidence showing the initial FDA approval date and whether the first FDA approval covered COPD.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The two evaluated claims concern FDA approval history, which is not directly used for dosing, contraindications, warnings, or administration. No patient-safety labeling content was asserted by these claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Approval-date and approval-sequencing claims are not supported by the provided prescribing information excerpt.
Suggested Improvement
Remove or revise claims about FDA approval date and what the first FDA approval covered unless supported by the provided label text or by label-adjacent documentation included in the audit inputs.